Dat	te:	_2021-03-01			
Υοι	ur Name:	:Qi Lei			
Ma	nuscript	Title:_G-rich seq	uence factor 1 serves a	s a prognostic biomarker in septic patients	
Ma	nuscript	number (if known):		
	-				
rela par to 1	ated to tl ties who transpare	he content of your ose interests may b ency and does not	manuscript. "Related" me e affected by the content	Il relationships/activities/interests listed below that are eans any relation with for-profit or not-for-profit third of the manuscript. Disclosure represents a commitment s. If you are in doubt about whether to list a lo so.	
	e followin		to the author's relationsh	nips/activities/interests as they relate to the <u>current</u>	
to	the epide	emiology of hypert		e <u>defined broadly</u> . For example, if your manuscript pertains e all relationships with manufacturers of antihypertensive the manuscript.	
			pport for the work report is the past 36 months.	ed in this manuscript without time limit. For all other item	s,
			is the past 36 months.		s,
			Name all entities with	Specifications/Comments	s,
			is the past 36 months.		s,
			Name all entities with whom you have this relationship or indicate none (add rows as	Specifications/Comments (e.g., if payments were made to you or to your	s,
			Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)	s,
	time fra	ame for disclosure i	Name all entities with whom you have this relationship or indicate none (add rows as	Specifications/Comments (e.g., if payments were made to you or to your institution)	s,
	All suppo	ame for disclosure i	Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)	s,
the	All suppo	ort for the present ript (e.g., funding,	Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initi	Specifications/Comments (e.g., if payments were made to you or to your institution)	s,
the	All suppo manuscri provision	ort for the present ript (e.g., funding, n of study materials,	Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initi	Specifications/Comments (e.g., if payments were made to you or to your institution)	s,
the	All suppo manuscri provision medical v	ort for the present ript (e.g., funding, or study materials, writing, article	Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initi	Specifications/Comments (e.g., if payments were made to you or to your institution)	s,
the	All suppo manuscri provision medical v	ort for the present ript (e.g., funding, n of study materials, writing, article ng charges, etc.)	Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initi	Specifications/Comments (e.g., if payments were made to you or to your institution)	s,
the	All suppo manuscri provision medical v	ort for the present ript (e.g., funding, or study materials, writing, article	Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initi	Specifications/Comments (e.g., if payments were made to you or to your institution)	s,
the	All suppo manuscri provision medical v	ort for the present ript (e.g., funding, n of study materials, writing, article ng charges, etc.)	Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initi	Specifications/Comments (e.g., if payments were made to you or to your institution)	s,
the	All suppo manuscri provision medical v	ort for the present ript (e.g., funding, n of study materials, writing, article ng charges, etc.)	Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initi None	Specifications/Comments (e.g., if payments were made to you or to your institution) al planning of the work	s,
the	All suppo manuscri provision medical v processir No time	ort for the present ript (e.g., funding, n of study materials, writing, article ng charges, etc.)	Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initi	Specifications/Comments (e.g., if payments were made to you or to your institution) al planning of the work	S,
the	All support manuscriprovision medical variations. No time	ort for the present ript (e.g., funding, of study materials, writing, article ng charges, etc.)	Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initiNone	Specifications/Comments (e.g., if payments were made to you or to your institution) al planning of the work	S,
the	All support manuscriprovision medical or processir No time	ort for the present ript (e.g., funding, of study materials, writing, article ng charges, etc.) limit for this item.	Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initiNone	Specifications/Comments (e.g., if payments were made to you or to your institution) al planning of the work	S,
the	All support manuscriprovision medical or processir No time Grants of any entitin item #	ort for the present ript (e.g., funding, of study materials, writing, article ng charges, etc.) limit for this item.	Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initiNone	Specifications/Comments (e.g., if payments were made to you or to your institution) al planning of the work	s,
the	All support manuscriprovision medical or processir No time Grants of any entitin item #	ort for the present ript (e.g., funding, n of study materials, writing, article ng charges, etc.) limit for this item.	Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initi √None Time frame: pas√_None	Specifications/Comments (e.g., if payments were made to you or to your institution) al planning of the work	s,

4

Consulting fees

	lectures, presentations, speakers bureaus, manuscript writing or		
6	educational events Payment for expert	√ None	
O	testimony	None	
	,		
7	Support for attending meetings and/or travel	_√None	
8	Patents planned, issued or	√_None	
	pending		
	2	1	
9	Participation on a Data Safety Monitoring Board or	√_None	
	Advisory Board		
10	Leadership or fiduciary role	√None	
	in other board, society,		
	committee or advocacy		
11	group, paid or unpaid	A Name	
11	Stock or stock options	None	
12	Receipt of equipment,	√None	
	materials, drugs, medical		
	writing, gifts or other		
12	services Other financial or non-	o/ Name	
13	financial interests	None	
	initialista interests		
Ple	ease summarize the above c	onflict of interest in the	following box:

5 Payment or honoraria for

√__None

4

Dat	te:	_2021-03-01			
Ma	Manuscript Title:_G-rich sequence factor 1 serves as a prognostic biomarker in septic patients				
Ma	nuscript	number (if known)	:		
related to the man of the man of the to the median of the	ated to the ties who cranspare ationship e following nuscript e author's the epide dication, tem #1 b	ne content of your se interests may be ency and does not a factivity/interest, and questions apply only. Is relationships/active even if that medical supply elow, report all supply and a supply elow, report all supply elow, report all supply sections.	manuscript. "Related" means affected by the content of the content of the cessarily indicate a bias. It is preferable that you do not to the author's relationship in the cesson, you should declare ation is not mentioned in the cesson.	ps/activities/interests as they relate to the <u>current</u> <u>defined broadly</u> . For example, if your manuscript pertains all relationships with manufacturers of antihypertensive	
			Name all entities with whom you have this	Specifications/Comments (e.g., if payments were made to you or to your	
			relationship or indicate none (add rows as needed)	institution)	
			Time frame: Since the initial	planning of the work	
1	All sunno	ort for the present	√ None		
-		pt (e.g., funding,			
		of study materials,			
		writing, article			
		ng charges, etc.)			
	No time	limit for this item.			
			Time frame: past	26 months	
2	Grants or	r contracts from	√ None	30 months	
_		y (if not indicated			
	in item #:	• •			
3	Royalties	or licenses	None		
	C 111		None.		
4	Consultin	ig tees	√None		

	lectures, presentations, speakers bureaus, manuscript writing or		
6	educational events Payment for expert	√ None	
O	testimony	None	
	,		
7	Support for attending meetings and/or travel	_√None	
8	Patents planned, issued or	√_None	
	pending		
	2	1	
9	Participation on a Data Safety Monitoring Board or	√_None	
	Advisory Board		
10	Leadership or fiduciary role	√None	
	in other board, society,		
	committee or advocacy		
11	group, paid or unpaid	A Name	
11	Stock or stock options	None	
12	Receipt of equipment,	√None	
	materials, drugs, medical		
	writing, gifts or other		
12	services Other financial or non-	o/ Name	
13	financial interests	None	
	initialista interests		
Ple	ease summarize the above c	onflict of interest in the	following box:

5 Payment or honoraria for

√__None

4

Consulting fees

Da	te:2021-03-01					
	Your Name:Li Ming					
Ma	Manuscript Title:_G-rich sequence factor 1 serves as a prognostic biomarker in septic patients					
Ma	anuscript number (if known)):				
rela par to	ated to the content of your rties whose interests may be	manuscript. "Related" mo e affected by the content necessarily indicate a bias	Il relationships/activities/interests listed below that are eans any relation with for-profit or not-for-profit third of the manuscript. Disclosure represents a commitment is. If you are in doubt about whether to list a o so.			
	e following questions apply inuscript only.	to the author's relationsh	nips/activities/interests as they relate to the <u>current</u>			
to		ension, you should declar	e <u>defined broadly</u> . For example, if your manuscript pertains e all relationships with manufacturers of antihypertensive the manuscript.			
	item #1 below, report all su e time frame for disclosure i	• •	ed in this manuscript without time limit. For all other items	s,		
		s the past 36 months.		s,		
		s the past 36 months. Name all entities with	Specifications/Comments	s,		
		s the past 36 months.		s,		
		Name all entities with whom you have this	Specifications/Comments (e.g., if payments were made to you or to your	s,		
		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)	s,		
		Name all entities with whom you have this relationship or indicate none (add rows as	Specifications/Comments (e.g., if payments were made to you or to your institution)	s,		
the	e time frame for disclosure i	Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)	s,		
the	All support for the present manuscript (e.g., funding,	Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initi	Specifications/Comments (e.g., if payments were made to you or to your institution)	s,		
the	All support for the present manuscript (e.g., funding, provision of study materials,	Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initi	Specifications/Comments (e.g., if payments were made to you or to your institution)	s,		
the	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article	Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initi	Specifications/Comments (e.g., if payments were made to you or to your institution)	s,		
the	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)	Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initi	Specifications/Comments (e.g., if payments were made to you or to your institution)	s,		
the	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article	Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initi	Specifications/Comments (e.g., if payments were made to you or to your institution)	s,		
the	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)	Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initi	Specifications/Comments (e.g., if payments were made to you or to your institution)	s,		
the	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)	Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initi	Specifications/Comments (e.g., if payments were made to you or to your institution) al planning of the work	S,		
the 1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)	Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initi	Specifications/Comments (e.g., if payments were made to you or to your institution) al planning of the work	S,		
	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initi None	Specifications/Comments (e.g., if payments were made to you or to your institution) al planning of the work	s,		
the 1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. Grants or contracts from	Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initi None	Specifications/Comments (e.g., if payments were made to you or to your institution) al planning of the work	s,		
the 1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. Grants or contracts from any entity (if not indicated	Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initi None	Specifications/Comments (e.g., if payments were made to you or to your institution) al planning of the work	s,		
1 2	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. Grants or contracts from any entity (if not indicated in item #1 above).	Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initi None Time frame: pasNone	Specifications/Comments (e.g., if payments were made to you or to your institution) al planning of the work	s,		

	lectures, presentations, speakers bureaus, manuscript writing or		
	educational events	Al Name	
6	Payment for expert testimony	None	
	testimony		
7	Support for attending meetings and/or travel	_√None	
8	Patents planned, issued or	√_None	
	pending		
•	Dantisia stiana ana Data	A Nove	
9	Participation on a Data Safety Monitoring Board or	√_None	
	Advisory Board		
10	Leadership or fiduciary role	√None	
	in other board, society,		
	committee or advocacy		
11	group, paid or unpaid Stock or stock options	√ None	
11	Stock of Stock options	_ \None	
12	Receipt of equipment,	√None	
	materials, drugs, medical		
	writing, gifts or other services		
13	Other financial or non-	√ None	
10	financial interests		
	ease summarize the above c	onflict of interest in the f	following box:

5 Payment or honoraria for

√__None

Da	te:	_2021-03-01				
Yo	ur Name:	Xu Cheng				
Ma	Manuscript Title:_G-rich sequence factor 1 serves as a prognostic biomarker in septic patients					
Ma	Manuscript number (if known):					
relipanto relimato mas	ated to the rties who transpare ationship e following nuscript the epide edication, item #1 b	ne content of your se interests may be ency and does not a factivity/interest, and questions apply only. Is relationships/activity of hyperto even if that medical elow, report all supersections.	manuscript. "Related" means affected by the content of the content of the cessarily indicate a bias. It is preferable that you do not to the author's relationship ivities/interests should be the cession, you should declare that it is not mentioned in the cession is not mentioned in the cession.	ps/activities/interests as they relate to the <u>current</u> <u>defined broadly</u> . For example, if your manuscript pertains all relationships with manufacturers of antihypertensive		
			Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)		
			Time frame: Since the initial	planning of the work		
1	manuscri	ort for the present pt (e.g., funding, of study materials,	VNone			
		writing, article				
	·	ng charges, etc.)				
	No time	limit for this item.				
			Time frame: past	26 months		
2	Grants or	contracts from	√ None	30 months		
•		y (if not indicated				
	in item #	• •				
3	Royalties	or licenses	√None			
1	Consultin	ng fees	None			
т	CONSUILL	ig iccs	\INUIIC			

	lectures, presentations, speakers bureaus, manuscript writing or		
6	educational events Payment for expert	√ None	
O	testimony	None	
	,		
7	Support for attending meetings and/or travel	_√None	
8	Patents planned, issued or	√_None	
	pending		
	2	1	
9	Participation on a Data Safety Monitoring Board or	√_None	
	Advisory Board		
10	Leadership or fiduciary role	√None	
	in other board, society,		
	committee or advocacy		
11	group, paid or unpaid	A Name	
11	Stock or stock options	None	
12	Receipt of equipment,	√None	
	materials, drugs, medical		
	writing, gifts or other		
12	services Other financial or non-	o/ Name	
13	financial interests	None	
	initialista interests		
Ple	ease summarize the above c	onflict of interest in the	following box:

5 Payment or honoraria for

√__None

Dat	te:2	2021-03-01			
Υοι	ır Name:Mao Guomin				
Ma	Manuscript Title:_G-rich sequence factor 1 serves as a prognostic biomarker in septic patients				
Ma	nuscript n	number (if known)	:		
related to the related The	ated to the ties whos transparer ationship/	e content of your e interests may be ncy and does not n activity/interest, g questions apply	manuscript. "Related" mea e affected by the content on necessarily indicate a bias. it is preferable that you do	relationships/activities/interests listed below that are ans any relation with for-profit or not-for-profit third of the manuscript. Disclosure represents a commitment If you are in doubt about whether to list a o so. ps/activities/interests as they relate to the current	
to t	the epider	niology of hyperte		defined broadly. For example, if your manuscript pertains all relationships with manufacturers of antihypertensive the manuscript.	
			oport for the work reporte s the past 36 months.	d in this manuscript without time limit. For all other item	is,
			Name all entities with	Specifications/Comments	
			whom you have this	(e.g., if payments were made to you or to your	
			relationship or indicate	institution)	
			none (add rows as		
			needed)		
.			Time frame: Since the initia	planning of the work	
1		t for the present	√None		
		ot (e.g., funding, of study materials,			
	•	riting, article			
		g charges, etc.)			
		mit for this item.			
			Time frame: past	36 months	
2	Grants or	contracts from	√ None		
		(if not indicated			
	in item #1				
3	Royalties	· · · · · · · · · · · · · · · · · · ·	√ None		

	lectures, presentations, speakers bureaus, manuscript writing or		
6	educational events Payment for expert	√ None	
U	testimony		
	,		
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or	√_None	
	pending		
_		1	
9	Participation on a Data Safety Monitoring Board or	√_None	
	Advisory Board		
10	Leadership or fiduciary role	√ None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	None	
12	Receipt of equipment,	√ None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	None	
	financial interests		
Ple	ease summarize the above c	onflict of interest in the	following box:
	None		

5 Payment or honoraria for

√__None

Date:_____2021-03-01_

Ma	ur Name:Liang Guiwei anuscript Title:_G-rich sequanuscript number (if known)	uence factor 1 serves as	a prognostic biomarker in septic patients
rel pa to	ated to the content of your rties whose interests may be	manuscript. "Related" me e affected by the content o necessarily indicate a bias.	relationships/activities/interests listed below that are ans any relation with for-profit or not-for-profit third of the manuscript. Disclosure represents a commitment If you are in doubt about whether to list a so.
	e following questions apply anuscript only.	to the author's relationshi	ps/activities/interests as they relate to the <u>current</u>
to me	the epidemiology of hypertoedication, even if that medic	ension, you should declare ation is not mentioned in t pport for the work reporte	defined broadly. For example, if your manuscript pertains all relationships with manufacturers of antihypertensive the manuscript. d in this manuscript without time limit. For all other items
		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	
4	Consulting fees	√None	

	lectures, presentations, speakers bureaus, manuscript writing or		
6	educational events Payment for expert	√ None	
U	testimony		
	,		
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or	√_None	
	pending		
_		1	
9	Participation on a Data Safety Monitoring Board or	√_None	
	Advisory Board		
10	Leadership or fiduciary role	√ None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	None	
12	Receipt of equipment,	√ None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	None	
	financial interests		
Ple	ease summarize the above c	onflict of interest in the	following box:
	None		

5 Payment or honoraria for

√__None

Date:_____2021-03-01_____

Ma	ur Name:Dong Yansor anuscript Title:_G-rich sequ anuscript number (if known)	uence factor 1 serves as	a prognostic biomarker in septic patients
rel pa to	ated to the content of your rties whose interests may be	manuscript. "Related" me e affected by the content on necessarily indicate a bias.	I relationships/activities/interests listed below that are ans any relation with for-profit or not-for-profit third of the manuscript. Disclosure represents a commitment If you are in doubt about whether to list a o so.
	e following questions apply anuscript only.	to the author's relationshi	ps/activities/interests as they relate to the <u>current</u>
to		ension, you should declare	defined broadly. For example, if your manuscript pertains all relationships with manufacturers of antihypertensive the manuscript.
	item #1 below, report all su e time frame for disclosure i		ed in this manuscript without time limit. For all other items
		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initia	l planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	
2	Grants or contracts from any entity (if not indicated in item #1 above).	Time frame: past √_None	36 months
3	Royalties or licenses	None	
4	Consulting fees	√None	

	lectures, presentations, speakers bureaus, manuscript writing or		
6	educational events Payment for expert	√ None	
U	testimony		
	,		
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or	√_None	
	pending		
_		1	
9	Participation on a Data Safety Monitoring Board or	√_None	
	Advisory Board		
10	Leadership or fiduciary role	√ None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	None	
12	Receipt of equipment,	√ None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	None	
	financial interests		
Ple	ease summarize the above c	onflict of interest in the	following box:
	None		

5 Payment or honoraria for

√__None

Date:_____2021-03-01_____

	ur Name:Yan Dajun						
	Manuscript Title:_G-rich sequence factor 1 serves as a prognostic biomarker in septic patients						
Ma	Manuscript number (if known):						
rel par to rel The ma	In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so. The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u> . The author's relationships/activities/interests should be <u>defined broadly</u> . For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript. In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.						
		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)				
		Time frame: Since the initia	planning of the work				
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None					
		Time frame: past	36 months				
2	Grants or contracts from any entity (if not indicated in item #1 above).	√_None					
3	Royalties or licenses	None					
4	Consulting fees	√ None					

	lectures, presentations, speakers bureaus, manuscript writing or		
6	educational events Payment for expert	√ None	
U	testimony		
	,		
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or	√_None	
	pending		
_		1	
9	Participation on a Data Safety Monitoring Board or	√_None	
	Advisory Board		
10	Leadership or fiduciary role	√ None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	None	
12	Receipt of equipment,	√ None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	None	
	financial interests		
Ple	ease summarize the above c	onflict of interest in the	following box:
	None		

5 Payment or honoraria for

√__None

Date:_____2021-03-01_____

	ur Name:Yan Yan						
	Manuscript Title:_G-rich sequence factor 1 serves as a prognostic biomarker in septic patients						
Ma	Manuscript number (if known):						
rel pa to rel Th ma							
		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)				
		Time frame: Since the initia	planning of the work				
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None					
		Time frame: past	36 months				
2	Grants or contracts from any entity (if not indicated in item #1 above).	√_None					
3	Royalties or licenses	None					
4	Consulting fees	√ None					

	lectures, presentations, speakers bureaus, manuscript writing or		
6	educational events Payment for expert	√ None	
U	testimony		
	,		
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or	√_None	
	pending		
_		1	
9	Participation on a Data Safety Monitoring Board or	√_None	
	Advisory Board		
10	Leadership or fiduciary role	√ None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	None	
12	Receipt of equipment,	√ None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	None	
	financial interests		
Ple	ease summarize the above c	onflict of interest in the	following box:
	None		

5 Payment or honoraria for

√__None

Da	te:2021-03-01_					
	Your Name:Huang Zhongwei					
	Manuscript Title:_G-rich sequence factor 1 serves as a prognostic biomarker in septic patients Manuscript number (if known):					
	-		ll relationships/activities/interests listed below that are			
pa to	rties whose interests n transparency and does	nay be affected by the content	eans any relation with for-profit or not-for-profit third of the manuscript. Disclosure represents a commitment . If you are in doubt about whether to list a o so.			
	e following questions a anuscript only.	apply to the author's relationsh	ips/activities/interests as they relate to the <u>current</u>			
to	the epidemiology of hy		e <u>defined broadly</u> . For example, if your manuscript pertains e all relationships with manufacturers of antihypertensive the manuscript.			
		all support for the work reporto sure is the past 36 months.	ed in this manuscript without time limit. For all other items,			
		Name all entities with	Specifications/Comments			
		whom you have this	(e.g., if payments were made to you or to your			
		relationship or indicate	institution)			
		none (add rows as				
		needed)				
	I	Time frame: Since the initia	al planning of the work			
1	All support for the prese manuscript (e.g., fundin	g,				
	provision of study mate medical writing, article	riais,				
	processing charges, etc.)				
	No time limit for this ite	·				
			100			
2	Grants or contracts fron	Time frame: pas	t 56 months			
_	any entity (if not indicat					
	in item #1 above).					
3	Royalties or licenses					

4

Consulting fees

	lectures, presentations, speakers bureaus, manuscript writing or		
6	educational events Payment for expert	√ None	
U	testimony		
	,		
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or	√_None	
	pending		
_		1	
9	Participation on a Data Safety Monitoring Board or	√_None	
	Advisory Board		
10	Leadership or fiduciary role	√ None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	None	
12	Receipt of equipment,	√ None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	None	
	financial interests		
Ple	ease summarize the above c	onflict of interest in the	following box:
	None		

5 Payment or honoraria for

√__None

Da	te:2021-03-01					
	Your Name:Sun Kai					
Ma	Manuscript Title:_G-rich sequence factor 1 serves as a prognostic biomarker in septic patients					
Ma	Manuscript number (if known):					
rel par to	ated to the content of your rties whose interests may be	manuscript. "Related" me e affected by the content necessarily indicate a bias	Il relationships/activities/interests listed below that are eans any relation with for-profit or not-for-profit third of the manuscript. Disclosure represents a commitment . If you are in doubt about whether to list a o so.			
	e following questions apply nuscript only.	to the author's relationsh	ips/activities/interests as they relate to the <u>current</u>			
to		ension, you should declare	defined broadly. For example, if your manuscript pertains all relationships with manufacturers of antihypertensive the manuscript.			
In i	tem #1 below, report all su	pport for the work reporte	ed in this manuscript without time limit. For all other items			
	e time frame for disclosure is	· -	•			
		· -				
		Name all entities with whom you have this	Specifications/Comments (e.g., if payments were made to you or to your			
		Name all entities with whom you have this relationship or indicate	Specifications/Comments			
		Name all entities with whom you have this relationship or indicate none (add rows as	Specifications/Comments (e.g., if payments were made to you or to your			
		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)			
the	e time frame for disclosure i	Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initia	Specifications/Comments (e.g., if payments were made to you or to your institution)			
the		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)			
the	All support for the present manuscript (e.g., funding, provision of study materials,	Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initia	Specifications/Comments (e.g., if payments were made to you or to your institution)			
	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article	Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initia	Specifications/Comments (e.g., if payments were made to you or to your institution)			
the	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)	Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initia	Specifications/Comments (e.g., if payments were made to you or to your institution)			
the	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article	Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initia	Specifications/Comments (e.g., if payments were made to you or to your institution)			
the	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)	Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initia	Specifications/Comments (e.g., if payments were made to you or to your institution)			
the	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)	Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initia	Specifications/Comments (e.g., if payments were made to you or to your institution) Il planning of the work			
the	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution) Il planning of the work			
the	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. Grants or contracts from	Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initia	Specifications/Comments (e.g., if payments were made to you or to your institution) Il planning of the work			
the	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution) Il planning of the work			
the	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. Grants or contracts from any entity (if not indicated	Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution) Il planning of the work			
1 2	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. Grants or contracts from any entity (if not indicated in item #1 above).	Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initia None Time frame: pasNone	Specifications/Comments (e.g., if payments were made to you or to your institution) Il planning of the work			

Consulting fees

	lectures, presentations, speakers bureaus, manuscript writing or		
6	educational events Payment for expert	√ None	
U	testimony		
	,		
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or	√_None	
	pending		
_		1	
9	Participation on a Data Safety Monitoring Board or	√_None	
	Advisory Board		
10	Leadership or fiduciary role	√ None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	None	
12	Receipt of equipment,	√ None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	None	
	financial interests		
Ple	ease summarize the above c	onflict of interest in the	following box:
	None		

5 Payment or honoraria for

√__None

Da	te:	_2021-03-01					
Yo	Your Name:Jiang Haiyan						
Ma	Manuscript Title:_G-rich sequence factor 1 serves as a prognostic biomarker in septic patients						
Ma	Manuscript number (if known):						
relipanto relimato mas	In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so. The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u> . The author's relationships/activities/interests should be <u>defined broadly</u> . For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript. In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.						
			Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)			
			Time frame: Since the initial	planning of the work			
1	manuscri provision medical v processir	ort for the present ipt (e.g., funding, of study materials, writing, article ng charges, etc.)	None				
			Time frame: past	36 months			
2		contracts from y (if not indicated 1 above).	√_None				
3	Royalties	or licenses	None				
4	Consultin	ng fees	√None				

	lectures, presentations, speakers bureaus, manuscript writing or		
6	educational events Payment for expert	√ None	
U	testimony		
	,		
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or	√_None	
	pending		
_		1	
9	Participation on a Data Safety Monitoring Board or	√_None	
	Advisory Board		
10	Leadership or fiduciary role	√ None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	None	
12	Receipt of equipment,	√ None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	None	
	financial interests		
Ple	ease summarize the above c	onflict of interest in the	following box:
	None		

5 Payment or honoraria for

√__None